Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

A Phase 1b, Single Ascending Dose, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Activity of SAR439459 in Adults With Osteogenesis Imperfecta

SAR439459 is a human anti-Transforming growth factor β (TGFβ) monoclonal antibody. This phase 1 clinical study investigates the safety, tolerability, and activity of a single dose of SAR439459 in adult participants with OI.

Participants will receive a single IV dose of SAR439459 with safety, pharmacokinetic (PK), and pharmacodynamic (PD) assessments over 24 weeks.

There will be up to 3 dose cohorts. In addition to safety, tolerability, and PK assessments, bone mineral density (BMD) will be evaluated by dual-energy Xray absorptimetry (DXA) scan and a series of blood biomarkers will be monitored to document pharmacodynamic effects of the single dose of SAR439459.

Study Overview

• Status: Terminated
• Conditions: Osteogenesis Imperfecta
• Intervention / Treatment: Drug: SAR439459; Drug: Placebo

Detailed Description

The duration of the study for all participants will be approximately 29 weeks:

• Up to 5 weeks from initiation of screening to dose administration
• Treatment on Day 1
• Follow-up and observation of safety and PD for 24 weeks
• Final study visit at Week 24

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Phase 1

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • Westmead, New South Wales, Australia, 2145
      • Westmead Hospital_Site Number :0360003
  • Victoria
    • Clayton, Victoria, Australia, 3168
      • Department of Medicine/ School of Clinical Sciences at Monash Health Monash University_246 Clayton Road_Site Number :0360002
• Canada
  • Toronto, Canada, M5G 2C4
    • Toronto general Hospital_Site Number :1240002
  • Ontario
    • Oakville, Ontario, Canada, L6M 1M1
      • Bone Research and Education Centre_Site Number :1240003
• France
  • Lyon, France, 69003
    • Hopital Edouard Herriot _Site Number :2500002
  • Paris, France, 75010
    • Hopital Lariboisiere_Site Number :2500001
• United States
  • California
    • Los Angeles, California, United States, 90095
      • UCLA Health_Site Number: 8400006
  • Connecticut
    • New Haven, Connecticut, United States, 06510
      • Yale University - Site Number:8400007
  • Indiana
    • Indianapolis, Indiana, United States, 46202
      • Indiana University School of Medicine_Site Number: 8400002
  • Maryland
    • Baltimore, Maryland, United States, 21205
      • Kennedy Krieger Institute_Site number 8400004
  • Ohio
    • Cincinnati, Ohio, United States, 45229
      • Cincinnati Children's Hospital Medical Center Site Number : 8400010
  • Tennessee
    • Nashville, Tennessee, United States, 37232
      • Vanderbilt University Site Number : 8400011
  • Texas
    • Houston, Texas, United States, 77030
      • Baylor College of Medicine - Site Number:8400003

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participants who are clinically categorized as Type I or IV osteogenesis imperfecta with a previously documented pathogenic genetic variant in human collagen type 1 alpha 1 gene (COL1A1) or human collagen type 1 alpha 2 gene (COL1A2).
• Participants who have experienced at least 1 bone fracture in the past 10 years OR 2 or more (≥2) fractures since the age of 18.
• Body weight ≥30.0 kg.
• Contraception for sexually active male participants or female patient; not pregnant or breastfeeding; no sperm donating for male participant.
• Signed written informed assent/consent.

Exclusion Criteria:

• Previously installed rods or metal hardware that would prevent bone mineral density evaluation of the lumbar spine (note: only two of the L1-L4 vertebrae are necessary for evaluation).
• History of moderate (25-40°) to severe (>40°) scoliosis assessed as Cobb angle (unless scoliosis does not impact assessment of bone mineral density in the lumbar vertebrae in the opinion of the investigator).

• Postmenopausal women who:

  • Are within 5 years of the onset of menopause (for example less than 5 years from their last menstruation or post-hysterectomy), however if the person has been on hormone replacement therapy for more than 1 year prior to enrollment, then they are eligible regardless of time from onset of menopause. The person must be willing to continue hormone replacement therapy throughout the study duration. OR
  • Were previously on hormone replacement therapy but have stopped within the past 5 years.
• History of treatment with denosumab, anti-sclerostin antibody, parathyroid hormone, bisphosphonates, or any other experimental therapy for OI within 6 months prior to any study baseline assessment.
• Known bleeding disorder.
• History of significant bleeding event that required hospitalization, surgery, or a blood transfusion that was possibly associated with increased bleeding tendency.
• Any major surgery within the last 28 days prior to investigational medicinal product (IMP) administration.
• Elective surgery or invasive procedure anticipated within 6 months after the IMP administration.
• Therapeutic doses of anticoagulants or antiplatelet agents (eg, 1 mg/kg bid of enoxaparin, 300 mg of aspirin daily, and 75 mg of clopidogrel daily or equivalent) within 7 days prior to the IMP administration.
• Any known central nervous system (CNS) or intraocular lesion that has a risk of bleeding.
• Prior history of skin cancers including melanoma, squamous cell carcinoma, or basal cell carcinoma.
• Clinically significant cardiac valvular disorder or symptomatic heart failure.
• Vitamin D (25-hydoxyvitamin D) <15 ng/dL; rescreening will be allowed after supplementation.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SAR439459; Participants will receive a single dose of SAR439459	Drug: SAR439459; Powder for solution for infusion; IV infusion
Placebo Comparator: Placebo; Participants will receive a single dose of placebo	Drug: Placebo; Solution for infusion; IV infusion

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of participants with adverse events (AEs)/treatment-emergent adverse events (TEAEs)	From baseline to Week 24

Secondary Outcome Measures

Outcome Measure	Time Frame
Assessment of PK parameters: area under the curve (AUC)	From baseline to Week 24
Assessment of PK parameters: maximum serum concentration observed (Cmax)	From baseline to Week 24
Assessment of PK parameters: time to reach maximum concentration observed (tmax)	From baseline to Week 24
Titer of anti-SAR439459 antibodies (if detected)	From baseline to Week 24
Percent change from baseline in bone mineral density (BMD)	From baseline to Week 24

Collaborators and Investigators

• Sponsor: Sanofi
• Investigators: Study Director: Clinical Sciences & Operations, Sanofi

Publications and helpful links

Helpful Links

• SAD17378 Plain Language Results Summary

Study record dates

Study Major Dates

• Study Start (Actual): August 25, 2022
• Primary Completion (Actual): November 12, 2024
• Study Completion (Actual): November 12, 2024

Study Registration Dates

• First Submitted: January 31, 2022
• First Submitted That Met QC Criteria: January 31, 2022
• First Posted (Actual): February 9, 2022

Study Record Updates

• Last Update Posted (Estimated): September 11, 2025
• Last Update Submitted That Met QC Criteria: September 4, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Bone Diseases; Musculoskeletal Diseases; Genetic Diseases, Inborn; Connective Tissue Diseases; Osteochondrodysplasias; Bone Diseases, Developmental; Collagen Diseases; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases; Osteogenesis Imperfecta; Substandard Drugs; Pharmaceutical Preparations; Counterfeit Drugs
• Other Study ID Numbers: SAD17378; U1111-1269-6569 (Registry Identifier: ICTRP); 2021-004914-21 (EudraCT Number); 2024-511369-12-00 (Registry Identifier: CTIS)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No